Protective Effect of Nicotinamide Riboside Against Acetaminophen Toxicity

NCT06214468 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-04-06

No results posted yet for this study

Summary

Over-the-counter drugs like acetaminophen (e.g., Tylenol®) can be detrimental. In space, astronauts who have pain and constant discomfort use acetaminophen extensively. Investigators are studying the effects of acetaminophen under space-like conditions since acetaminophen might affect astronauts' health. Investigators also wish to see whether a dietary supplement can reduce some negative effects of acetaminophen.

It is believed that acetaminophen promotes the productions of chemicals in the body that could be toxic.

In this study, measurements of these chemicals in urine after ingestion of 1 tablet of acetaminophen and compare these measurements to when acetaminophen is taken at the same time as a dietary supplement. This study will also explore whether these products are more abundant when blood is placed under conditions that mimic space. Therefore, this study will collect blood from a few volunteers who took acetaminophen, and acetaminophen with the dietary supplement.

Conditions

  • Drug Toxicity

Interventions

COMBINATION_PRODUCT

Acetaminophen and Nicotinamide Riboside

Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside

DRUG

Acetaminophen

Collection of urine at different time intervals following ingestion of Tylenol only

Sponsors & Collaborators

  • National Aeronautics and Space Administration (NASA)

    collaborator FED
  • University of Nevada, Las Vegas

    collaborator OTHER
  • University of Alabama at Birmingham

    collaborator OTHER
  • Rutgers University

    collaborator OTHER
  • University of South Alabama

    lead OTHER

Principal Investigators

  • marie migaud, PHD · University of South Alabama

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2025-04-01
Completion
2025-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06214468 on ClinicalTrials.gov